(News Bulletin 247) – AstraZeneca and Merck announced that the United States Food & Drug Administration (FDA) has approved Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and with BRCA mutation (BRCAm).
In the United States, prostate cancer is the second most common cancer in men, and despite an increase in the number of treatments available for patients with mCRPC, five-year survival remains low.
In addition, approximately 10% of patients with mCRPC will have BRCA mutations, which are associated with poor prognosis and poorer outcomes.
‘The results of [de l’essai] showed that therapy including Lynparza demonstrated remarkable clinically significant benefit that should quickly be considered the gold standard treatment for patients with BRCAm mCRPC’, commented Andrew Armstrong, Duke Cancer Institute, Durham, NC and researcher from the ‘essay.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
